Vascular endothelial growth factor (VEGF) and Ang1 (Angiopoietin-1) have opposing effects on vascular permeability, but the molecular basis of these effects is not fully known. We report in this paper that VEGF and Ang1 regulate endothelial cell (EC) junctions by determining the localization of the RhoA-specific guanine nucleotide exchange factor Syx. Syx was recruited to junctions by members of the Crumbs polarity complex and promoted junction integrity by activating Diaphanous. VEGF caused translocation of Syx from cell junctions, promoting junction disassembly, whereas Ang1 maintained Syx at the junctions, inducing junction stabilization. The VEGF-induced translocation of Syx from EC junctions was caused by PKD1 (protein kinase D1)-mediated phosphorylation of Syx at Ser806, which reduced Syx association to its junctional anchors. In support of the pivotal role of Syx in regulating EC junctions, syx−/− mice had defective junctions, resulting in vascular leakiness, edema, and impaired heart function.
Regulation of the paracellular permeability of the endothelial cell (EC) monolayer is essential for the normal function of the vascular system, and its impairment has severe pathological effects. VEGF and Ang1 (Angiopoietin-1) play essential but opposite roles in the regulation of EC junctions and vessel permeability. The molecular mechanisms through which these ligands affect vessel permeability are known partially. VEGF increases vessel permeability by disrupting intercellular junctions through a signaling pathway that includes Src tyrosine kinase (Weis and Cheresh, 2005). Ang1, on the other hand, opposes the effect of VEGF by sequestering Src (Gavard et al., 2008) and stabilizing intercellular junctions. In epithelial cells, junction stability is modulated by the apicobasal polarity complexes CRB (Crumbs–Pals–Patj), PAR (Par3–Par6–atypical PKC), and SCRIB (Scribble–Dlg–Lgl; Tepass, 1996; Qin et al., 2005; Dow and Humbert, 2007). The underlying molecular mechanism and the role of these polarity complexes in EC junction maintenance are unknown.
Rho GTPases constitute a major class of polarity protein and intercellular adhesion effectors (Fukata et al., 2003; Hall, 2005; Iden and Collard, 2008). Junction homeostasis appears to require a precise level of RhoA activity: both hyper- and hypoactivation of RhoA increased paracellular permeability (Braga et al., 1997; Popoff and Geny, 2009; Spindler et al., 2010). Furthermore, the effect of RhoA on cell junctions depends on the agonist: RhoA stabilized junctions in response to Ang1 but destabilized them in response to VEGF (Gavard et al., 2008). The regulation of RhoA by polarity complexes and its signaling at cell junctions are poorly understood.
RhoA binds to and is activated by guanine nucleotide exchange factors (GEFs). We found that the RhoA-specific (De Toledo et al., 2001; Marx et al., 2005) synectin-binding RhoA exchange factor (Syx; Fig. 1 A) is localized to EC tight junctions (TJs). Syx is involved in EC migration (Liu and Horowitz, 2006) and regulates angiogenesis in both the zebrafish and mouse (Garnaas et al., 2008). In this study, we uncovered an unexpected relationship between key members of the CRB polarity complex and the regulation of cell junctions by Syx and RhoA. The localization of Syx, a previously unrecognized member of the CRB polarity complex, emerged as a key factor determining junction stability in vitro and vessel permeability in vivo and conferring the opposite effects of Ang1 and VEGF on EC junctions.
Syx associates with cell junctions and is required for junction integrity
To identify novel regulators of Rho GTPases at cell junctions, we expressed a library of mammalian Rho GEFs in MDCK cells and screened it for junctional localization and for interaction with junctional proteins. Both endogenous and overexpressed YFP-tagged Syx colocalized with ZO1 in human umbilical vein ECs (HUVECs) and in confluent MDCK cells, respectively (Fig. 1 B), indicating that it is a novel junctional Rho GEF.
Using immunoprecipitation of YFP-Syx followed by mass spectrometry analysis, we verified that Syx associated with the scaffold protein Mupp1 (multiple PDZ domain protein 1; Estévez et al., 2008; Ernkvist et al., 2009), synectin (also named Gipc1; Liu and Horowitz, 2006; Ernkvist et al., 2009), Lin7, and the protein associated with Lin7 (Pals1). We also found novel interactions with 14-3-3 proteins; Fig. S1 A and Table S1). These associations, as well as the interaction of Syx with the Mupp1 paralogue Patj (Pals1-associated with TJs), were verified by coimmunoprecipitation and by colocalization of ectopically expressed or endogenous proteins in HUVECs and in neonatal human dermal microvascular ECs (HMVECs; Fig. S1, B–I). With the exception of 14-3-3, the association of these proteins depended on the C-terminal PDZ-binding motif (PBM) of Syx.
Several of the Syx-interacting partners are members of the apical CRB complex (Fig. 1 C), which promotes the integrity of intercellular junctions, as well as apicobasal polarity (Tepass, 1996; Klebes and Knust, 2000; Shin et al., 2005). To determine whether Syx is a key member of this complex, we first tested whether it is required for TJ stability and function. Knockdown of either syx or mupp1 by each of two nonoverlapping shRNAs markedly reduced their expression level (Figs. 1 D and S2 B) and produced a fragmented ZO1 staining pattern in confluent HUVECs and HMVECs (Figs. 1, E and G; and S2, A–C).
The CRB complex has been implicated also in the stability of adherens junctions (AJs), which are required for the maintenance of monolayer integrity (Tepass, 1996; Dejana et al., 2009). Mature AJs reorganize the cortical actin cytoskeleton into circumferential rings that are critical for monolayer integrity. We found that knockdown of syx in HUVEC monolayers abolished the circumferential actin localization (Fig. 1 E) and reduced the localization of VE-cadherin to intercellular contact sites in HUVECs (Fig. 1 F) and in HMVECs (Fig. 1 G). The increased distribution of VE-cadherin in the cytosol (Fig. 1 F) correlated with increased VE-cadherin endocytosis in Syx-depleted HUVECs (Fig. S2, D and E).
To determine the functional consequences of the observed junctional defects, we measured trans-endothelial impedance during the formation of postmitotic, confluent HUVEC monolayers expressing syx (Fig. 1 H) or control shRNA. The impedance of both monolayers at 4,000 Hz climbed during the first 20 h after plating, but from that point onward, the impedance of the syx shRNA-treated monolayer plateaued, indicating that it had achieved its maximum patency. In contrast, the impedance of monolayers treated by control shRNA continued climbing to a plateau higher by ∼30% than the syx shRNA-treated monolayers (Fig. 1 I). The difference in impedance between the two monolayers cannot be attributed to cell density or cell death because cell numbers in each sample were very similar and remained so during the 2 d of the assay (Fig. 1 J). This result indicates that Syx is required for the formation of a fully patent monolayer. Put together, these data indicate that Syx promotes intercellular junction stability and monolayer integrity.
syx−/− mice have defective EC junctions and leaky vessels
We used the angiogenesis-deficient syx−/− mouse (Garnaas et al., 2008) to study the in vivo role of Syx in cell junctions. Using ZO1 as a junction marker, we found that it was present as a continuous band in 80% of syx+/+ ECs but in <20% of syx−/− ECs (Fig. 2, A and B), despite a similar expression level (Fig. 2 C). The impedance of syx−/− EC monolayers increased at a lower rate than that of syx+/+ monolayers during the first 4 h and reached a plateau that was lower by 40% than the syx+/+ impedance at 48 h (Fig. 2 D). Cell numbers in the monolayers of each type were similar (unpublished data). This result indicates that junction formation by syx−/− ECs is slower and that their junctions reach a lower steady-state patency compared with syx+/+ ECs. We then quantified vessel patency in vivo by measuring microsphere extravasation from the tracheal venules of syx+/+ and syx−/− mice. The latter was more than sixfold higher on average than that of syx+/+ mice (Fig. 2, E and F). Because the vasculature of the syx−/− mouse is sparser than that of the syx+/+ counterpart (Garnaas et al., 2008), the higher extravasation from the syx−/− vessels cannot be attributed to a larger vascular length or volume. To rule out the possibility that the leakiness of the syx−/− venules reflected defects in non-EC types, we repeated the extravasation assays in a tie2-Cresyxfl/fl mouse model. Albeit lower than the extravasation of syx−/− venules, the extravasation from tie2-Cresyxfl/fl tracheal venules was more than sevenfold higher than in control syxfl/fl venules (Fig. 2, E and F). Using transmitted electron microscopy, we observed that the intercellular junctions between mural ECs of syx−/− coronary capillaries were malformed or absent (Fig. 2 G). In syx+/+ mice, areas of intercellular contact between capillary ECs were closely juxtaposed and electron dense. On the other hand, ECs of syx−/− capillaries had tenuous intercellular contacts with reduced electron density or did not contact each other at all (Fig. 2 G). Furthermore, erythrocytes were present in the interstitial space of the Syx−/− myocardium (Fig. 2 H), consistent with other mouse models exhibiting morphologically similar junctional defects that also suffered from hemorrhage (Cattelino et al., 2003; Feng et al., 2006).
Edema can impair cardiac function by increasing the passive stiffness of the myocardium (Miyamoto et al., 1998; Fischer et al., 2006). To find whether the capillary leakage we observed affected the mechanical properties of the syx−/− heart, we measured the pressure–volume relation in syx+/+ and syx−/− left ventricles subjected to partial aortic occlusion. The responses of the syx+/+ and syx−/− left ventricles were vastly different: the difference between the end-diastolic and end-systolic volumes of the syx−/− ventricle was much smaller (Fig. 2 I), resulting in a smaller ejection fraction. Because we found no structural differences at the sarcomere level between the syx+/+ and syx−/− myocardia (Fig. S2 F), the pressure–volume loop differences are unlikely to result from defective myocardial contractility. The aberrant pressure–volume relation of the syx−/− left ventricle could have been caused, at least in part, by an alteration in the mechanical properties of the walls because of edema. We derived the passive stiffness of the left ventricle by calculating the slope of the linear approximation of the end-diastolic pressure–volume relation (Katz, 2006). The resulting passive stiffness of the syx−/− ventricle was twice as high as that of the syx+/+ ventricle (Fig. 2 J). Therefore, our in vitro and in vivo results corroborate each other, showing that Syx is required for the maintenance of EC junctions and blood vessel patency.
Diaphanous (Dia) stabilizes cell junctions downstream of Syx
Previous studies have shown that Syx is a RhoA-specific GEF and that depletion of Syx in ECs results in a significantly reduced RhoA activity (De Toledo et al., 2001; Marx et al., 2005; Liu and Horowitz, 2006). Localized activation of RhoA at epithelial AJs is important for junction assembly and maintenance (Terry et al., 2011). Therefore, we postulated that junction-localized Syx promotes junction stability. To test this premise, we used YFP-Syx, which we previously showed to activate RhoA at the cell membrane (Liu and Horowitz, 2006), and YFP-Syx-ΔPBM (Fig. S3 A), which induces RhoA activation in the cytosol (Liu and Horowitz, 2006). Despite inducing equivalent levels of RhoA activation (Fig. S3 B), YFP-Syx localized at intercellular junctions and induced junctional actin accumulation (a telltale sign of mature AJs), whereas YFP-Syx-ΔPBM was cytosolic and increased the number of stress fibers (Fig. S3, C and D). Furthermore, the N terminus region of Syx (Syx-N) inhibited the GEF activity of the endogenous Syx (Fig. S3 E and not depicted) and strongly suppressed junction formation when expressed at low levels, similar to the Rho selective inhibitor C3 exotransferase (Fig. S3 F). These data argue strongly that Syx activates RhoA to promote junction integrity.
The regulation of intercellular junctions and permeability by RhoA is complex and is likely regulated by the subsequent activation of downstream effectors (Braga et al., 1997; Takaishi et al., 1997; Sahai and Marshall, 2002; Wojciak-Stothard and Ridley, 2002; Popoff and Geny, 2009; Terry et al., 2011). Signaling through the RhoA-associated kinases ROCK1 and ROCK2 has been related to both negative (Sahai and Marshall, 2002) and positive (Terry et al., 2011) effects on junction integrity. Suppression of Rho-associated protein kinase (ROCK) activity by overnight treatment with either Y-27632 or H1152 (10 µM) did not significantly affect junction integrity of control HUVECs, as assessed by ZO1 and actin staining (Fig. 3 A). Instead, ROCK inhibition partially restored junctional ZO1 and actin localization in HUVECs expressing syx shRNA (Fig. 3 A). Because ROCK activation cannot account for Syx effects at EC junctions, we next asked whether Dia stabilized junctions downstream of Syx. Dia is thought to prevent VE-cadherin endocytosis and to maintain junctional stability by inhibiting Src (Gavard et al., 2008). Similarly, Dia promotes E-cadherin stabilization and the establishment of a cortical actin ring in epithelial cells (Sahai and Marshall, 2002), downstream of RhoA (Carramusa et al., 2007). We found that expression of a constitutively active N-terminally truncated Dia1 mutant (Dia1ΔN3; Watanabe et al., 1999) in cells depleted of endogenous Syx restored the junctional localization of ZO1 (Fig. 3 B). The Dia-mediated rescue of junctional ZO1 staining was equivalent to that of rescuing Syx-depleted cells by expressing exogenous murine Syx (Fig. 3 C). Consistent with an involvement of Src in these effects, Syx depletion induced the activation of Src kinase (Figs. 3 D and S3 G, quantification), and pharmacological inhibition of Src in Syx-depleted HUVECs partially restored the junctional localization of ZO1 (Fig. 3 E). Therefore, our data indicate that junction-targeted Syx is required for the localized activation of Dia by RhoA, resulting in the stabilization of intercellular junctions.
Syx acts downstream of CRB polarity members to regulate junction integrity
The interaction of Syx with members of the CRB complex and its localization to cell junctions require the C terminus PBM (Fig. S1, C–E). Synectin and Mupp1 bind directly to Syx via their PDZ domains in yeast two-hybrid screens (Liu and Horowitz, 2006; Estévez et al., 2008; Ernkvist et al., 2009). Furthermore, Pals1 and Mupp1 interact directly via their L27 domains (Roh et al., 2002). Depletion of endogenous Mupp1 reduced the association of Syx with Pals1, without affecting binding of Syx to synectin (Fig. S4 A). In contrast, depletion of Pals1 did not affect the interaction of Syx with Mupp1 but reduced overall Mupp1 levels (Fig. S4 B), in agreement with the effect of Pals1 on the stability of the Mupp1 paralogue Patj (Straight et al., 2006). Similar to Syx, knockdown of Mupp1 also disrupted junction morphology (Figs. 4 A and S2, A–C). However, although depletion of Syx had little effect on the recruitment of Mupp1 to the remaining cell contacts, depletion of Mupp1 abolished the junctional recruitment of either endogenous (Fig. 4 A) or exogenous Syx (Fig. 4 B). The data argue strongly that targeting of Syx to EC junctions requires binding to Mupp1.
Consistent with the hypothesis that Syx acts downstream of the CRB polarity complex to promote junction stabilization, depletion of Mupp1 induced the activation of Src kinase (Fig. 4 C). Similar to Syx-depleted cells (Fig. 3, A and E), inhibition of either ROCK or Src activities largely reversed the junctional defects of Mupp1-depleted cells (Fig. 4 D). Combined, the data argue that Syx is a novel member and a key downstream effector of the CRB polarity complex in the regulation of junction integrity.
Ang1 and VEGF reciprocally regulate the localization of Syx
Endothelial intercellular adhesion is regulated reciprocally by Ang1 and by VEGF. Because cell junction strengthening in response to Ang1 requires Rho-mediated activation of Dia, suppression of Src, and VE-cadherin stabilization (Gavard et al., 2008), we tested whether Ang1-mediated junction stabilization requires Syx. Ang1 treatment increased the localization of Syx at junctions (Fig. 5, A, D, and E, quantitation of Syx intensity at junctions). The junctional accumulation of either VE-cadherin or ZO1 (quantified in Fig. 5 B) was dramatically disrupted in cells expressing syx-targeted shRNA and was not rescued by treating cells with Ang1. Consistent with this, Syx depletion prevented the Ang1-induced enhancement of barrier function. The role of Syx in the regulation of barrier function by Ang1 was determined by measuring the impedance of postmitotic, confluent HUVEC monolayers treated by control or by syx shRNA. Whereas Ang1 increased the impedance of the control monolayers, it had no effect on the impedance of cells treated by syx shRNA (Fig. 5 C).
In contrast to Ang1, VEGF disrupts EC junctions (Olsson et al., 2006). In accordance, VEGF treatment (Fig. S4 C) had the same effect as depletion of Syx (Fig. 1, E and F) on VE-cadherin and ZO1 localization at cell junctions and on cortical actin organization. Strikingly, VEGF caused displacement of Syx from cell junctions at a time when the junctional ZO1 pattern became irregular, suggesting that TJs were disassembling (Figs. 5, D and E, quantification; and S4 G). Importantly, this loss of Syx from cell junctions was blocked by pretreatment for 15 min with Ang1 (Fig. 5, D and E). Ang1 pretreatment also prevented the VEGF-induced loss of junctional integrity, as reflected in the increased accumulation of VE-cadherin and ZO1 at cell junctions. We also compared the relative impedance of quiescent HUVEC monolayers treated with PBS to those treated with VEGF, Ang1, or Ang1 together with VEGF. VEGF caused an early increase followed by a sustained decrease in monolayer impedance (Fig. 5 F). Ang1 induced a small increase in impedance, probably because the monolayer had already reached full patency. Ang1 pretreatment (15 min) delayed and largely negated the VEGF effect during the 60-min observation period, suggesting that barrier function closely correlates with Syx localization.
To test whether Syx regulates EC junctions in vivo, we compared the leakage of Evans blue dye from the skin of syx+/+ and syx−/− mice in response to injections of PBS, VEGF-A165, or Ang1. The leakage of dye from the syx−/− skin was more than threefold higher than the syx+/+ skin (Fig. 5 G). VEGF treatment did not further increase the leakiness of syx−/− skin. Moreover, Ang1 was ineffective in diminishing the leakage from the syx−/− skin, in contrast to the syx+/+ skin. The leakage from Ang1-treated syx−/− skin was close to ninefold higher than the leakage from syx+/+ skin. Therefore, the in vivo data are consistent with the sustained responses of our ECs in vitro to either VEGF or Ang1. Collectively, the data support a model whereby VEGF induces junction disassembly and increases monolayer permeability by displacing Syx from the junctions, and conversely, Ang1 stabilizes junctions and sustains vessel patency at least in part by maintaining Syx at the junctions.
Phosphorylation downstream of VEGF and PKD1 regulates Syx localization
To determine whether VEGF induces the loss of junctional Syx by promoting its dissociation from Mupp1, we immunoprecipitated endogenous Syx from control (PBS) or from VEGF-treated HUVECs. Fig. 6 A (quantitation of Mupp1 bands in Fig. S4 D) shows that less Mupp1 was coimmunoprecipitated by Syx in VEGF-treated cells. Further supporting the dissociation of Syx from Mupp1, VEGF treatment had little effect on the junctional localization of Mupp1 (Fig. S4, E and F). A clue to the mechanism by which VEGF affects Syx localization came from the observation that PMA induced identical effects to VEGF on Syx localization and on ZO1 pattern in HUVECs (Fig. S4 G). As PKD is a critical downstream effector of both VEGF- and PMA-induced angiogenesis (Fig. S4 H; Taylor et al., 2006; Altschmied and Haendeler, 2008; Ha and Jin, 2009), we asked whether it regulates Syx-Mupp1 binding and alters Syx’s subcellular localization. Using an antibody (pMotif) that recognizes PKD-phosphorylated motifs (Döppler et al., 2005), we detected selective phosphorylation of immunoprecipitated YFP-Syx but not of the other 21 Rho GEFs tested (Fig. S5 A). PMA treatment (Fig. S5 B) and overexpression of either wild-type or constitutively active (but not kinase dead) PKD1 (Fig. S5 C) increased the phosphorylation level of Syx. Importantly, phosphorylation of YFP-Syx was blocked by silencing endogenous pkd1 and pkd2 (Fig. S5 D). Consistent with these results and with the high level of PKD1 expression in HUVECs (Fig. S5 E), we observed a significant increase in Syx phosphorylation in VEGF-treated HUVECs (Fig. 6 B). Additionally, PKD1 colocalized with Syx at cell junctions and in the cytoplasm after VEGF treatment (unpublished data). Finally, as with VEGF, the increase in Syx phosphorylation in response to PMA correlated strongly with decreased binding between Syx and Mupp1 (Fig. S5, F and G).
A potential PKD phosphorylation site was detected in Syx by deletion mutagenesis in the C terminus region beyond residue 757 (Fig. S5 H). Sequence analysis identified two potential PKD phosphorylation motifs in that region, at Ser806 and Ser938 (Fig. S5 I), whereas phosphopeptide mapping identified an additional site at Ser964. Mutation of Ser938 and Ser964 to Ala did not reduce recognition by the pMotif antibody upon PKD overexpression. Recognition was abolished, however, by mutating Ser806 to Ala (Fig. S5 J). The possibility that another kinase acting downstream of PKD phosphorylates Syx at a classical PKD consensus motif cannot be excluded by our data but is unlikely. The simplest explanation is that VEGF and PMA induce Syx phosphorylation at Ser806 by a common downstream effector, PKD, disrupting Syx binding to Mupp1 and, therefore, Syx localization to cell junctions.
Because Syx phosphorylation correlated with reduced association to Mupp1 (Figs. 6, A and B; and S5, F and G), we asked whether phosphorylation at Ser806 could regulate the binding of Syx to Mupp1 and thus affect the junctional localization and function of Syx. First, we used YFP as a tag to immunoprecipitate full-length YFP-Syx or Syx carrying a S806A mutation from HeLa cells overexpressing PKD1. The amount of Mupp1 coimmunoprecipitated with Syx-S806A was approximately twice larger than the one coimmunoprecipitated with Syx (Fig. 6 C), confirming that S806 regulates Syx binding to Mupp1. When expressed in HUVECs, more cells expressing YFP-Syx-S806A exhibited junctional Syx localization than cells expressing YFP-Syx (Fig. 6, D and E). Importantly, VEGF treatment abolished the junctional localization of YFP-Syx but failed to significantly affect the localization of YFP-Syx-S806A at cell junctions (Fig. 6, D and E). These data indicate that phosphorylation of Syx at S806 is a major mechanism by which VEGF regulates the recruitment of Syx to EC junctions.
Here, we reveal a new signaling pathway that transduces both VEGF and Ang1 signaling and explains how these ligands induce opposite effects on EC junctions and vessel permeability. The switch that determines the outcome of this pathway is the RhoA-specific GEF Syx. The removal of Syx from the junctions downstream of VEGF results in their disassembly, whereas Ang1 stabilizes junctions by activating Dia through junction-residing Syx. In addition to junction formation (Sahai and Marshall, 2002; Carramusa et al., 2007; Gavard et al., 2008), Dia reportedly also promotes focal adhesion turnover (Yamana et al., 2006). In agreement, silencing syx increased stress fiber density (Fig. 1 E), whereas ROCK inhibitors partially rescued junction defects induced by either Syx or Mupp1 depletion in confluent monolayers (Figs. 3 A and 4 D). These results are consistent with the antagonistic relationship between Dia and ROCK in junction maintenance (Sahai and Marshall, 2002) and suggest that Syx acts downstream of Mupp1 and the CRB complex to induce junction integrity by activating Dia and antagonizing ROCK (Fig. 7, proposed model).
The critical function of Syx in vascular homeostasis is highlighted by our observation that syx−/− mice exhibit EC junction defects, vascular leakiness, edema, increased passive stiffness, and lower ejection fraction. Ang1 regulates vascular leakiness, vascularization, and inflammation as well as tumor cell intra- and extravasation (Suri et al., 1996; Thurston et al., 1999, 2000; Huang et al., 2010). The observation that Syx is required for Ang1-mediated stabilization of EC junctions in vitro and in vivo is therefore consistent with the increased leakiness and the decreased vascularization of syx−/− mice (Garnaas et al., 2008) and raises questions as to the potential role of Syx in inflammation and/or tumor metastasis.
On the other hand, VEGF induces translocation of Syx and junction disassembly. By incorporating the new signaling events described here, PKD1 activation and phosphorylation of Syx at S806, we can delineate an entire VEGF signaling pathway ending in the disassembly of cell junctions: VEGF binding to VEGFR2 (VEGF receptor 2) induces VEGFR2 autophosphorylation at Y1173, which promotes the binding of PLC and subsequent activation of a PLC–IP3 pathway, leading to enhanced extracellular Ca2+ entry via the plasmalemmal store-operated channel TRCP1 (transient receptor potential canonical-1; Jho et al., 2005) and the subsequent activation of PKC-α (Olsson et al., 2006). The latter then activates PKD1 by phosphorylating S744 and S748 on its activation loop (Wong and Jin, 2005). In turn, PKD1 promotes phosphorylation of Syx at S806, resulting in its dissociation from Mupp1 and translocation to the cytoplasm. Removal of junctional Syx reduces Dia activity, resulting in Src activation (Gavard et al., 2008), leading to increased phosphorylation and destabilization of both AJ (Esser et al., 1998; Gavard et al., 2008) and TJ (Antonetti et al., 1999; Pedram et al., 2002) complexes, inducing junction disassembly (Fig. 7). Junction stability and barrier function are further compromised by increased contractility, presumably because of Dia deactivation and the subsequent reorganization of F-actin away from cell junctions, to focal adhesions and stress fibers (Yamana et al., 2006). Ang1 opposes VEGF-induced Ca2+ entry (Jho et al., 2005) and therefore PKC–PKD activation, thus providing a mechanistic explanation for its ability to retain Syx at the junctions.
PKD1 may act both upstream of RhoA by regulating Syx at the junctions and downstream of it by affecting actin dynamics. Indeed, PKD1 regulates F-actin–free barbed-end formation at the leading edge of migrating epithelial cells, downstream of RhoA and ROCK (Eiseler et al., 2009). Although this pathway has not been investigated in ECs, ROCK-activated PKD1 could further disrupt endothelial junctions by displacing Syx.
Importantly, RhoA and Src signaling have been previously implicated in several physiological and pathological conditions that depend on endothelial junction disassembly (Weis and Cheresh, 2005; Parikh et al., 2006; Gavard et al., 2008; Mackow and Gavrilovskaya, 2009). Maintaining the function of junctional Syx may therefore be therapeutically relevant in diseases characterized by vascular leakiness and edema.
Materials and methods
Cells and transfection
Heart EC isolation from adult mice (8–16 wk) followed a previously published technique (Dong et al., 1997). In brief, mouse hearts were minced and digested by collagenase I (Sigma-Aldrich). ECs were sorted by anti-Pecam1 (BD) immobilized to magnetic beads (Invitrogen), expanded, and sorted again as before, producing a >95% EC-pure preparation. The HeLa and MDCK cells were cultured in DMEM (Cellgro) with 10% fetal bovine serum (Invitrogen). HUVECs and HMVEC-dermal neonatal (Lonza) were cultured in EGM-2 (Endothelial Growth Medium-2) and EGM-2MV, respectively (Lonza). HeLa and MDCK cells were transfected with TransIT-HeLaMONSTER (Mirus Bio LLC) and Lipofectamine 2000 (Invitrogen), respectively, according to the manufacturer’s instructions. HUVEC’s were transfected with HUVEC Nucleofector kit (Amaxa) according to the manufacturer’s instructions.
EC-specific disruption of murine
LoxP sites flanking exons 10–16 (containing the catalytic Dbl homology domain of murine Syx) were inserted by homologous recombination. Heterozygous mice were crossed with germline Cre mice to excise the targeted region in all mouse tissues. Mice harboring EC-specific disruption of syx were obtained by crossing syx(loxP/loxP) and tie2-Cre (B6.Cg-Tg(Tek_cre)1Ywa/J; Jackson ImmunoResearch Laboratories, Inc.) mice.
Vectors, antibodies, and reagents
pEYFP-C1-mSyx, pEYFP-C1-mSyxΔPBM, N-terminally His-tagged mSyx truncation mutants, RK5-myc-LIN-7 and RK5-myc-PATJ (provided by B. Margolis, University of Michigan, Ann Arbor, MI), pEGFP-mDia1ΔN3 (provided by S. Narumiya, Kyoto University, Kyoto, Japan), and pCDNA3.1 HA-PKD wild-type, kinase-active, and kinase-dead constructs have been previously described (Kamberov et al., 2000; Ishizaki et al., 2001; Wang et al., 2004; Döppler et al., 2005; Liu and Horowitz, 2006). Point mutations of serine to alanine were introduced into pEYFP-mSyx using multisite-directed mutagenesis kit (QuikChange; Agilent Technologies). mSyx truncation mutants were generated by cloning specific coding sequences (Syx N terminus, amino acids 1–300; SyxΔNΔC, amino acids 291–800; SyxΔNter, amino acids 291–1,073) from pEYFP-mSyx into pEYFP-C1 using HindIII and BamHI as restriction sites. All constructs generated were sequenced to ensure no mutation was present.
The following antibodies were used: mouse anti-Plekhg5 (KIAA0720 clone 5A9; Abnova); mouse anti–E-cadherin, anti-EEA1, and anti-Mupp1 (BD); rabbit anti-Src (32G6), antiphospho-Src (Tyr416), and antimyc tag (Cell Signaling Technology); mouse anti-GFP 3E6, mouse anti-ZO1, monoclonal rabbit anti-GFP, and rabbit anti-ZO1 (Invitrogen); hamster and rat anti-Pecam1 (Thermo Fisher Scientific and BD, respectively); rabbit anti–PKC-μ, anti–14-3-3β, anti-Rho (26C4), anti-Pals1 (H-250), mouse anti-GIPC (C-9), goat anti–VE-cadherin (C-19; Santa Cruz Biotechnology, Inc.); mouse anti–VE-cadherin (BV6; EMD Millipore); mouse anti-FLAG, antipoly-Histidine, and rabbit antiactin (Sigma-Aldrich); and rabbit polyclonal antibody for pMOTIF was previously described (Döppler et al., 2005) as well as immunofluorescence-competent chicken anti–human Syx and rabbit anti-Mupp1 (provided by R. Javier, Baylor College of Medicine, Houston, TX; Lee et al., 2000; Liu and Horowitz, 2006). Phalloidin 594 (Invitrogen) was used to stain for actin filaments in immunofluorescence experiments. DAPI was used to stain nuclei. Alexa Fluor 488 and Alexa Fluor 594 fluorescently conjugated secondary antibodies were obtained from Invitrogen and Jackson ImmunoResearch Laboratories, Inc.
PMA (Sigma-Aldrich) and PP2 (EMD Millipore) were dissolved in DMSO to 100 and 10 µM, respectively. Human recombinant VEGF was dissolved in sterile PBS to 10 ng/ml (EMD Millipore). Recombinant human Ang1 was dissolved in sterile PBS to 50 ng/ml (R&D Systems). Y-27632 (Sigma-Aldrich) and H1152 (EMD Millipore) were dissolved in sterile water to 100 µM.
Affinity purification and mass spectrometry
YFP or YFP-tagged Syx was transfected into HeLa cells. Cell lysates were incubated with protein G beads (Invitrogen) precoated with anti-GFP (Invitrogen). Bound proteins were eluted, resolved by SDS-PAGE, and silver stained. Selected gel bands were destained, reduced, and alkylated before digestion with trypsin (Promega). Samples were analyzed using a hybrid mass spectrometer (ThermoFinnigan LTQ Orbitrap; Thermo Fisher Scientific). Mascot (Matrix Science) was used to search the Swiss-Prot database to identify isolated peptides.
shRNA and lentivirus production
Lentiviral vectors (pLKO) encoding a nontarget shRNA sequence along with human-specific shRNA target sequences for Syx and Mupp1 were purchased (Syx RNAi 1, TRCN0000130291; Syx RNAi 2, TRCN0000128190; Mupp1 RNAi 1, TRCN0000141979; and Mupp1 RNAi 2, TRCN0000145218; Thermo Fisher Scientific). 15 µg of packaging mix (ViraPower; Invitrogen) and 5 µg of the plasmid were transfected in 293FT cells (Invitrogen) using Lipofectamine 2000. 24 h later, the virus-containing media were harvested and used to infect HUVEC, HMVEC, or HeLa cells. Cells were selected with 2.5 µg/ml puromycin (Sigma-Aldrich) for 18–24 h. Freshly infected HUVECs were harvested and replated in ECIS (electric cell-substrate impedance system) chambers for impedance measurements of monolayer barrier function.
Immunofluorescence, immunoprecipitation, and immunoblotting
Cells were plated on coverslips (type I collagen coated for HUVECs; fibronectin coated for HMVECs; BD), fixed with methanol or 3% paraformaldehyde as previously reported (Anastasiadis et al., 2000), and probed with primary antibodies followed by incubation with secondary antibodies. For HUVECs, 4 × 105 cells were resuspended in 100 µl EGM, plated on coverslips, and allowed to adhere for 5 min; for HMVECs, 2 × 105 cells were resuspended in 400 µl EGM-2MV, plated on coverslips, and allowed to adhere for 5 min. Medium was subsequently added into the wells, and the cell monolayer was maintained for 3 d before experiments were performed. VE-cadherin internalization experiments were performed according to Xiao et al. (2003). In brief, HUVECs were incubated in endothelium basal medium with anti–VE-cadherin (BV6) for 30 min at 4°C followed by antibody uptake for 30 min at 37°C in endothelium basal medium and then acid washed (10 min) to remove cell surface–bound antibody. Cells were then fixed and stained and then imaged at room temperature with a laser-scanning confocal microscope (LSM 510 META; Carl Zeiss) using Plan Neofluar 40×/1.3 NA or Plan Apochromat 63×/1.4 NA oil immersion objectives. Raw images acquired at the same intensity and exposure settings with the ZEN 2009 software (Carl Zeiss) were analyzed for junctional Syx or internalized VE-cadherin intensities using ImageJ (National Institutes of Health). Endogenous Syx was immunoprecipitated by a mouse monoclonal antibody (KIAA0720; Abnova). Protein samples were analyzed using SDS-PAGE, transferred to nitrocellulose, and probed with primary antibodies. Peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, Inc.) were detected by luminescence (GE Healthcare).
Impedance measurement of endothelial barrier function
An electric cell substrate impedance system (ECIS Z; Applied BioPhysics) was used to measure the impedance of either HUVEC or primary mouse EC monolayers, as previously described in detail by Tiruppathi et al. (1992). In brief, cells (HUVECs, 105 cells/well; primary mouse ECs, 5 × 104 cells/well) were plated in ECIS Cultureware Disposable Electrode Arrays (8W10E; Applied BioPhysics) precoated with collagen. After attachment to ECIS arrays, monolayers were allowed to adhere and become quiescent for 48 h. Treatments (PBS, VEGF at 50 ng/ml, and/or Ang1 at 50 ng/ml) were added directly into the wells at the indicated times. Impedance was measured every 180 s for the duration of the entire experiment. Impedance data at 4,000 Hz, representing current flow between the cells, are presented as is or normalized to the impedance value at the beginning of the experiment. Excel (Microsoft) was used for data analysis, and Prism 4 (GraphPad Software) software was used for all graphing purposes. All data presented are representative of three independent experiments.
Rho activity assay
Rho activity was determined in HeLa cells using specific rhotekin pull-down assays (Cytoskeleton) for the activated form of the protein as previously described (Soto et al., 2008). In brief, lysates of HeLa cells transfected with the respective constructs were cleared by centrifugation and incubated with 20 µg Rhotekin–Rho-binding domain beads (Cytoskeleton) for 1 h at 4°C. Beads were then washed three times and eluted in boiling 2× Laemmli sample buffer, and the samples were analyzed by SDS-PAGE.
Mice anesthetized by 2.5% isoflurane were euthanized by injecting saturated KCl solution. Mice were perfused by PBS, pH 7.4, through the carotid artery followed by 4% paraformaldehyde, which was washed out by PBS. Hearts were fixed by 15-min immersion in 3% glutaraldehyde, 2% paraformaldehyde, and 0.1 M cacodylate buffer, pH 7.4, containing 0.1 M sucrose and 3 mM CaCl2. Hearts were sliced into sections, fixed in same solution for 30 min, and cut down to ∼1-mm3 blocks followed by 24 h fixation at 4°C. Tissue blocks were fixed in 1% osmium tetroxide for 2 h and embedded in epoxy resin (Araldite; Sigma-Aldrich). Blocks were cut into 6-µm sections on a microtome. Images were acquired on a transmission electron microscope (JEM-1010; JEOL).
Mice anesthetized by 100 mg/kg ketamine and 10 mg/kg xylazine were injected intraperitoneally by 100 IU heparin followed by 100 µl of 1:10 diluted fluorescent 25-nm microspheres (Thermo Fisher Scientific) through the carotid vein. The microspheres were allowed to circulate for 2 min before the chest was opened. The vascular system was perfused with 1% paraformaldehyde/PBS, pH 7.4, through the left ventricle for 2 min at a constant pressure of 120 mmHg. The trachea was removed and incubated in 1% paraformaldehyde/PBS, pH 7.4, for 2 h at room temperature and then cut longitudinally and blocked by 3% BSA in PBS with 0.3% Triton X-100 for 1 h followed by anti-Pecam1 (Thermo Fisher Scientific) and fluorescently conjugated secondary antibody. Extravasation was measured by quantifying microsphere fluorescence in each image.
Leakage of dye from skin vessels (Miles assay)
Mice anesthetized as in the previous paragraph were injected through the tail vein by 200 µl Evans blue (0.5%). After 10 min, shaved areas on the flanks of each mouse were injected by 50 µl PBS, 10 ng/ml VEGF-A165, or 50 ng/ml Ang1. After 20 min, mice were sacrificed by cervical dislocation, and the skin around the sites of injections was dissected and flipped over to acquire digital images of dye leakage on the underside of the skin. The extent of leakage at each injection site was quantified from the images by Image-Pro (Media Cybernetics).
Pressure–volume measurements in the mouse
Mice positioned in dorsal recumbence were anesthetized with 2.5% isoflurane in oxygen, intubated, and ventilated at 133 breaths per minute with a peak inspiratory pressure <20 cm H2O. Temperature was maintained at 37.5°C. Lactated Ringer’s solution was delivered at 0.2 ml/h through a jugular catheter. A pressure–volume catheter (1.4 F; Millar Instruments) was inserted into the carotid artery, and the isoflurane was lowered to 1.75%. Pressure and volume were recorded with the MPVS-400 system (Millar Instruments) and analyzed by PVAN software (Millar Instruments). Baseline carotid blood pressure was recorded at the reduced isoflurane level before introducing the catheter introduced into the left ventricle. Baseline loops were recorded after a stabilization period of ∼20 min. A bolus of 2–3 µl of 9% saline was injected into the jugular vein. Pressure–volume loops generated immediately after saline injection were used to determine left ventricle conductance as part of the conversion to volume units. Isoflurane levels were increased briefly to 2–2.25%, and a suture loop was placed on the transverse aorta. After a period of 10–15 min of stabilization and reduced isoflurane, the loop was tightened, and the pressure and volume were recorded immediately. This was repeated to obtain at least four series of pressure–volume loops for calculation of the end-systolic and end-diastolic pressure–volume relationship.
Statistical significance was analyzed by Student’s t test and expressed as a p-value.
Online supplemental material
Fig. S1 shows the interaction and colocalization of Syx with identified binding partners and the requirement of the PDZ-binding motif for these interactions. Fig. S2 shows the effects of Mupp1 and Syx depletion on junction integrity of HUVECs and HMVECs and on VE-cadherin endocytosis in HUVECs, respectively. Fig. S3 shows that the localization of Syx at areas of cell–cell contact and RhoA activation are important for cell–cell adhesion. Fig. S4 shows the VEGF/PMA-induced translocation of Syx away from junctions is caused by loss of Syx binding to Mupp1. Fig. S5 represents a series of experiments validating PKD-mediated phosphorylation of Syx at Ser806. Table S1 shows Syx-interacting proteins.
We thank Drs. Shuh Narumiya, Ben Margolis, Ronald Javier, Judy Drazba, Edward Plow, Roy Silverstein, Qingyu Wu of the Cleveland Clinic Foundation, Mark McNiven (Mayo Clinic, Rochester, MN), Albert Reynolds (Vanderbilt University, Nashville, TN), Alejandro Adam (Albany Medical College, Albany, NY), and Mr. Christopher Ogomo (Dartmouth Medical School, Hanover, NH) for providing reagents, technical support, and critical comments. We thank Ben Madden and the Mayo Proteomics Research Center for their assistance with mass spectrometry analysis.
The work was supported by National Institutes of Health grants R01 CA100467, R01 NS069753, and R21 NS070117 (to P.Z. Anastasiadis), R01 HL086854 (to A. Horowitz), DA-00266 (to J.M. Baraban), and R01 GM086435-1 (to P. Storz), American Heart Association Scientist Development Grant 0635235N, the Hitchcock Foundation (to M. Liu), National Research Service Award HL007914 (to C. Wu and S. Agrawal), and the Mayo Graduate School (to S.P. Ngok).
end-diastolic pressure–volume relation
guanine nucleotide exchange factor
human dermal microvascular EC
human umbilical vein EC
Rho-associated protein kinase
S.P. Ngok and R. Geyer contributed equally to this paper.